EU Regulator Eyes Mid-September For Decision On Comirnaty BA.4/BA.5 Booster Approval
Agency Also Expects Adapted Spikevax Filing From Moderna This Month
As regulators continue to process and approve applications for new kinds of COVID-19 booster vaccines, evidence is still awaited on the real-world benefits conferred by the latest variant-adapted products. The European Medicines Agency and the European Centre for Disease Prevention and Control plan to issue a joint statement on the use of adapted vaccines next week, and the EMA has OKd a booster version of the Novavax vaccine.
You may also be interested in...
Coronavirus Notebook: UK OKs Second Bivalent Vaccine, European Companies Warn On Joint Vaccine Procurement Plans
The Swiss medicines regulator has approved the bivalent version of Spikevax and given the green light to use of the Novavax COVID-19 vaccine in younger people.
EU OKs Bivalent COVID-19 Vaccines From Pfizer/BioNTech & Moderna
The European Commission will shortly issue marketing authorizations for bivalent versions of Comirnaty and Spikevax targeting the Omicron BA.1 subvariant, after the European Medicines Agency recommended their approval for EU-wide use. Bivalent Spikevax has also been provisionally approved in Australia.
EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.